{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3150","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"comment":"The median was not reached and therefore, could not be calculated.","groupId":"OG000","lowerLimit":"84.14","upperLimit":"NA","value":"NA"},{"comment":"The median was not reached and therefore, could not be calculated.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2061"},{"groupId":"OG001","value":"2075"}],"units":"Participants"}],"description":"Disease-free survival was defined as the time from the date of randomization to the date of the first documentation of re-occurrence of invasive breast cancer in local, regional or distant sites, new invasive breast cancer in the contra-lateral breast, or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"2.5 mg by mouth (p.o.) once daily","id":"OG000","title":"Letrozole"},{"description":"1 mg p.o. once daily","id":"OG001","title":"Anastrozole"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.","reportingStatus":"POSTED","timeFrame":"84 months","title":"Disease Free Survival","type":"PRIMARY","unitOfMeasure":"Months"}